TP53 and neoplasm: IR can initiate the export of BRCA1 from the nucleus to the cytoplasm, leading to increased sensitivity of PARPi in wild-type BRCA1 and HR-proficient tumor cells [129, 130] However, because of the synthetic lethality of the combination therapy is p53-depend, it can only be used in wild-type p53 patients [131].